Background

In modern life sciences research, post-translational modifications (PTMs) are increasingly recognized as playing a central role in the regulation of cellular functions and signal transduction. PTMs chemically modify proteins, thereby altering their activity, stability, and interactions, which in turn influence fundamental biological processes such as cell growth, differentiation, and apoptosis. These modifications encompass a variety of forms, including phosphorylation, acetylation, ubiquitination, and glycosylation, and they play an indispensable role in cell biology and cancer research.

Liman ELEMab series antibodies The ubiquitination-enriched antibody (Catalog No.: LMMSPTM0300) was used in this study. For details, please see ： Product Launch | “Ubiquitination-Enrichment Antibodies” in the Protein Degradation Drug Product Portfolio , Feel free to contact us for a sample.

1. SCASP-PTM: An Innovative Technology for Multi-PTM Analysis

A recent article published in Cell Reports provides a detailed description of a novel technique called SCASP-PTM (SDS Cyclodextrin Assisted Sample Preparation for PTM). This method enables the salt-free, continuous enrichment of multiple post-translational modifications (PTMs) in a sample without the need for complex purification steps, thereby facilitating data-independent acquisition mass spectrometry (DIA-MS) analysis. At the heart of SCASP-PTM is its highly efficient sample preparation workflow, which leverages cyclodextrin in combination with SDS to mitigate the effects of protein denaturants, thus achieving robust enrichment of diverse PTMs.

Traditional PTM analysis methods typically require separate sample preparation and analysis for each type of modification, which is not only time-consuming but also prone to sample loss and analytical errors. The SCASP-PTM technology integrates multiple enrichment strategies, including TiO2, IMAC, and CaTiO3, enabling the simultaneous analysis of various post-translational modifications such as phosphorylation, acetylation, ubiquitination, and glycosylation. This innovative approach significantly enhances experimental efficiency and data accuracy, providing a powerful tool for PTM research.
 

2. New Insights into the Degradation Mechanism of p62 Protein

Within cells, the p62/SQSTM1 protein serves as a critical autophagy receptor, playing a pivotal role in maintaining cellular homeostasis by mediating protein degradation and regulating signaling pathways. Studies have demonstrated that aberrant expression of p62 is closely associated with a variety of diseases, including neurodegenerative disorders and cancer. In this study, SCASP-PTM technology revealed that GSK3β-mediated phosphorylation of p62 at Ser28 is a key driver of its degradation. Using HeLa-S3 cells, the researchers found that phosphorylated p62 is more readily degraded by the proteasome, a process that can be blocked by the proteasome inhibitor MG132.

This discovery offers a new perspective on our understanding of the complex mechanisms underlying protein degradation and may serve as a reference for developing relevant therapeutic strategies. The degradation of p62 is not only influenced by its own phosphorylation status but may also involve interactions with other signaling pathways. Future research could further investigate the specific mechanisms of these interactions to achieve a more comprehensive understanding of p62’s role in both physiological and pathological cellular states.

3. The Relationship Between ALDOA Protein and Tumor Progression

In multi-PTM proteomics studies of lung cancer, significant ubiquitination and acetylation modifications at lysine residue 330 of the ALDOA (aldolase A) protein have been identified. ALDOA is a glycolytic enzyme that plays a critical role in metabolic reprogramming in cancer cells. Research indicates that these post-translational modifications of ALDOA are key drivers of tumor growth and progression.

Through analysis of lung cancer tissue samples, researchers found that ALDOA expression is significantly higher in tumors than in normal tissues, and that the degree of modification at its K330 site is also markedly upregulated. Further functional experiments demonstrated that the K330R mutation enhances ALDOA’s enzymatic activity while slowing cell growth and migration. These findings highlight the critical role of ALDOA in tumor cell proliferation and migration, providing a theoretical basis for its potential as a therapeutic target.

Ubiquitination and acetylation of ALDOA may promote metabolic adaptation and invasive capacity in tumor cells by modulating its enzymatic activity and protein–protein interaction network. Future studies could further investigate the role of ALDOA in different types of tumors and how its post-translational modifications influence tumor biological behavior.

4. Potential for Clinical Application

The clinical application potential of SCASP-PTM technology is primarily reflected in the following aspects:

• Discovery of biomarkers: Through systematic analysis of PTMs in tumor tissue and cell samples, the SCASP-PTM technology can facilitate the identification of novel biomarkers. These biomarkers not only hold promise for early diagnosis and prognostic assessment but may also guide the development of personalized therapeutic strategies.
• Identification of therapeutic targets: PTMs play a crucial role in regulating protein function and signaling pathways. The SCASP-PTM technology, by elucidating the molecular mechanisms underlying these pathways, may facilitate the identification of novel therapeutic targets, which is of great significance for the development of drugs targeting specific PTMs.
• Investigation of drug mechanisms of action: By analyzing changes in protein post-translational modifications (PTMs) in cells or tissues before and after drug treatment, the SCASP-PTM technology can be used to elucidate drug mechanisms of action. This will help optimize existing therapeutic regimens and facilitate the development of new drugs.
• Advancing personalized medicine: SCASP-PTM technology enables comprehensive analysis of post-translational modifications (PTMs) in patient samples, thereby providing data-driven support for personalized treatment. By identifying patient-specific PTM profiles, clinicians can select the most appropriate therapeutic regimen, ultimately enhancing treatment efficacy.

5. Challenges and Future Directions

Although SCASP-PTM technology has demonstrated significant potential in PTM research, it still faces several challenges. First, the technique is primarily optimized for common PTM types; for rare or low-abundance PTMs, its enrichment efficiency and detection sensitivity still require further improvement. Second, the dynamic nature and complexity of PTMs necessitate the consideration of multiple factors in experimental design and data analysis to ensure the accuracy and reproducibility of results.

Future research can further enhance the application value of SCASP-PTM technology through the following avenues:

• Technical optimization: Enhancing the detection of low-abundance and rare PTMs through improved sample preparation and enrichment methods. Integration of novel mass spectrometry technologies further boosts analytical sensitivity and resolution.
• Development of data analysis tools: As PTM data accumulate, more advanced data analysis tools and algorithms should be developed to better process and interpret complex PTM datasets. This will help elucidate the functions and mechanisms of PTMs in biological processes.
• Multi-omics integration analysis: Integrating SCASP-PTM technology with genomics, transcriptomics, metabolomics, and other multi-omics datasets for comprehensive analysis. This will facilitate the construction of more comprehensive biological networks and reveal the systemic roles of PTMs in the regulation of cellular functions.
• Clinical Translational Research: By closely integrating with clinical studies, this research evaluates the real-world effectiveness of SCASP-PTM technology in disease diagnosis, treatment, and prognosis, thereby facilitating the translation of this technology from laboratory research into clinical practice.

Summary and Outlook

The SCASP-PTM technology offers a new perspective for understanding tumor biology and demonstrates its broad potential for application in post-translational modification research. As the technology continues to be refined and its scope of application expands, SCASP-PTM is poised to play an increasingly significant role in clinical diagnosis and treatment, thereby contributing to the challenge of conquering cancer. In the future, researchers will continue to explore the potential applications of SCASP-PTM in other diseases and strive to develop more efficient and precise methods for PTM analysis. By closely integrating with clinical research, SCASP-PTM holds the promise of opening new avenues for personalized medicine and precision therapy.

References

Lin ZP, et al. Comprehensive PTM profiling with SCASP-PTM uncovers mechanisms of p62 degradation and ALDOA-mediated tumor progression. Cell Rep. April 3, 2025; 44(4):115500. doi: 10.1016/j.celrep.2025.115500. Epub ahead of print. PMID: 40186868.